Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Privately-held immuno-oncology company Immune-Onc Therapeutics has announced a Phase Ib/II trial collaboration with Swiss pharma giant Roche. 22 February 2024
Pharmaceutical
Italian pharma major Recordati saw its shares dip 1.5% to 51.30 euros today, despite releasing a strong set of financial results for full year 2023. 22 February 2024
Biotechnology
US pharma major Bristol Myers Squibb has announced the investment of $400 million into a company facility in Dublin, Ireland. 22 February 2024
Pharmaceutical
India's pharma landscape has undergone a significant shift towards collaboration and partnership between global big pharma and domestic firms in recent years to drive innovation and expand market reach, according to GlobalData. 21 February 2024
Biotechnology
The UK subsidiary of Swiss pharma giant Novartis is recalling Adakveo (crizanlizumab) 10mg/ml concentrate for solution for infusion. 21 February 2024
Biotechnology
The USA’s Creating Hope Reauthorization Act of 2024 was introduced in the House of Representatives last week, prompting US trade group Biotechnology Innovation Organization (BIO) chief executive and president, Rachel King, to make the following statement following the bill's introduction: 21 February 2024
Biotechnology
US RNA-focussed biotech Avidity Biosciences says that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to AOC 1044. 20 February 2024
Pharmaceutical
GlobalData has taken a look at shifts in market capitalization among the world’s top 20 biopharma companies during 2023. 20 February 2024
Pharmaceutical
Australia’s Starpharma has announced that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel BV (SPL7013/astodrimer sodium). 20 February 2024
Biotechnology
In 2023, more than 50% (28 of 55) of the novel drugs reviewed by the US Food and Drug Administration (FDA) received orphan drug designation for the prevention, diagnosis, or treatment of a rare disease.1 20 February 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze